EUCTR2016-001641-79-GB进行中（未招募）1 期
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administered ALS-008176 Regimens in Infants and Children Aged 1 to 36 Months Hospitalized with Respiratory Syncytial Virus
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female infant who is =28 days to =36 months of age, inclusive, defined at the time of randomization.
- •2. Hospitalized (or in emergency room prior to hospitalization) at the time of randomization and unlikely to be discharged for the first 24 hours after randomization.
- •3. Diagnosed with RSV infection based on a PCR-based molecular diagnostic assay (Note: in cases where commercial PCR-based assays are not available at the site, the sponsor should be consulted for agreement on the assay to be used) with or without co-infection with another respiratory pathogen (eg, influenza, human metapneumovirus, or bacteria).
- •4. The time of onset of RSV symptoms to the time of randomization must be =5 days. Onset of symptoms is defined as the first time (within 1 hour) the parent(s)/caregiver(s) becomes aware of respiratory or systemic symptoms of RSV infection. At the recommendation of the IDMC, this duration may be decreased or increased to up to 7 days. If this occurs, the Independent Ethics Committees (IECs)/Institutional Review Boards (IRBs) will be notified promptly, without the need for a formal protocol amendment.
- •5. With the exception of the RSV-related illness or defined comorbid condition for severe RSV bronchiolitis (prematurity at birth [for infants <1 year old at randomization], bronchopulmonary dysplasia, congenital heart disease, other congenital diseases, Down Syndrome, neuromuscular impairment, or cystic fibrosis) the subject must be medically stable on the basis of physical examination, medical history, vital signs, and ECG performed at screening. If there are abnormalities, they must be consistent with the underlying condition in the study population. This determination must be recorded in the subject’s source documents and initialed by the investigator.
- •6. Medically stable on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel or hematology are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study (RSV-related illness or defined comorbid conditions for severe RSV bronchiolitis). This determination must be recorded in the subject’s source documents and initialed by the investigator. A single repeat laboratory evaluation is allowed for eligibility determination.
- •7. Estimated glomerular filtration rate (GFR) is not below the lower limit of normal for the subject’s age (Schwartz equation calculation).
- •8. In the investigator’s opinion, the subject’s legally acceptable representative understands and is able to comply with protocol requirements, instructions, and protocol stated restrictions, and subject is likely to complete the study as planned.
- •9. Their legally acceptable representative must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing for the subject to participate in the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 120
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number o
排除标准
- •1. Subject has known or suspected immunodeficiency (except immunoglobulin A [IgA] deficiency), such as known human immunodeficiency virus infection.
- •2. Receipt of (within the last 12 months) or currently on a waiting list for a bone marrow, stem cell or solid organ transplant, receipt of radiation or chemotherapy within 12 months prior to screening, or currently taking immunosuppressive medication.
- •3. Subjects who are anticipated to be treated with other agents with potential antiviral activity against RSV (eg, ribavirin, IV immunoglobulin, palivizumab).
- •4. History of or concurrent illness (beyond a defined comorbid condition for severe RSV bronchiolitis) that in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol-specified assessments such as liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, metabolic disturbances, or genetic diseases that result in immunosuppression. These may include, but are not limited to bacteremia, organ dysfunction, or other severe comorbidities.
- •5. Poorly functioning gastrointestinal tract (ie, unable to absorb drugs or nutrition via enteral route). Note: the use of IV fluids is not exclusionary so long as the investigator believes the subject’s gastrointestinal tract still functions properly (ie, is able to absorb drugs or nutrition).
- •6. Subject is being treated with extracorporeal membrane oxygenation.
- •7. Subject receiving chronic oxygen therapy at home prior to admission.
- •8. Taking any disallowed therapies before the planned first dose of study drug.
- •9. Received an investigational drug, an investigational vaccine, or used an invasive investigational medical device within 30 days or 5 half-lives (whichever is longer) before the planned first dose of study drug or is currently enrolled in an investigational study.
- •10. Planned or current participation in another interventional clinical study during this study.
- •11. Known allergies, hypersensitivity, or intolerance to ALS-008176 or its excipients.
- •12. Being breastfed by a mother taking any of the excluded medications.
- •13. Subject’s legally acceptable representative ie, parent(s)/legal guardian/caregiver(s), is not able to communicate reliably with the investigator.
- •14. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate whether NEOD001 is safe and effective in subjects with light chain AL amyloidosis affecting the heart.ight chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble,fibrillar deposits of abnormal AL protein (amyloid),in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac,renal,and hepatic dysfunction,gastrointestinal involvement and neuropathy and macroglossiaMedDRA version: 20.0Level: PTClassification code 10036673Term: Primary amyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2015-004318-14-DEProthena Therapeutics Limited129
进行中（未招募）
1 期
A controlled clinical trial to study RM-131 (relamorelin) in patients with vomiting symptoms and diabetic gastroparesisVomiting symptoms in patient with moderate to severe diabetic gastroparesisMedDRA version: 17.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-005623-27-BERhythm Pharmaceuticals, Inc.395
进行中（未招募）
1 期
A double-blind, placebo-controlled Clinical Trial to evaluate the Safety and Efficacy of JNJ-64304500 in patients with Moderately to Severely Active Crohn’s DiseaseEUCTR2016-000634-21-HUJanssen-Cilag International NV693
进行中（未招募）
1 期
A study to investigate the effects of lumicitabine (JNJ-64041575) in hospitalized adults infected with human metapneumovirusHuman metapneumovirus infectionMedDRA version: 20.0Level: PTClassification code 10066226Term: Metapneumovirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001696-22-SEJanssen-Cilag International NV180
进行中（未招募）
1 期
A Phase 2b study for adults hospitalized with Respiratory Syncytial Virus.MedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsRespiratory Syncytial Virus InfectionEUCTR2016-001653-40-PLJanssen-Cilag International NV216